Ajanta Pharmaceuticals credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−650−650−488−393−780
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.15×−0.15×−0.13×−0.12×−0.24×
−0.44×−0.54×−0.41×−0.35×−1.12×
397.38×397.38×231.48×145.19×109.43×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AJANTPHARM₹3,459.70

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹43,367 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Net Debt-780.2-393.1-488.4-650.4-650.4
Net Debt/Equity-0.24-0.12-0.13-0.15-0.15
Net Debt/EBITDA-1.12-0.35-0.41-0.54-0.44
Interest Coverage (EBIT/Interest)109.43145.19231.48397.38397.38
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.